



Figure S1 Evaluation of the performance of the dapagliflozin PBPK model. Comparison of simulated (lines) with observed (symbols \pm SD) concentrations of dapagliflozin. Panel A: oral administrations of 2.5-500 mg reported in the single ascending dose (SAD) study.^{27,37} Panel B: oral administrations of 2.5-100 mg on the 14th day of the multiple ascending dose (MAD) study.^{27,37} Panel C: iv administrations to dogs, monkeys, rats, and humans.^{25,26} Panel D: simulated versus observed concentrations of dapagliflozin for the 19 simulated datasets. The identity line represents a perfect accordance of simulation with observed data. The diagonal lines above and below the identity line mark the 2- and 0.5-fold deviation ranges, respectively. Grey shaded areas – concentrations below and above reported (accurate) quantification limits.